No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | 9,358 | 13,115 | 23,204 | 23,376 | 16,083 | 13,971 | 14,250 | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | 1,048 | 2,382 | 3,684 | 3,255 | 2,049 | 1,575 | 1,672 | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Balaji Amines Limited, an Indian company, specializes in the production and global distribution of methylamines, ethylamines, their associated derivatives, alongside a diverse portfolio of specialty chemicals and pharmaceutical excipients. The firm's business activities span three primary divisions: Amines & Speciality Chemicals, its Hotel operations, and CFL Lamp manufacturing. Within its chemical segment, Balaji Amines produces a wide range of amines, including monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, and dimethyl/diethyl amino ethanol. Its specialty chemicals encompass compounds like N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, and acetonitrile. Additionally, the company provides derivatives such as di-methyl acetamide, various amine hydrochlorides (di-methyl, tri-methyl, di-ethyl, tri-ethyl), di-methyl urea, and choline chloride. For the pharmaceutical industry, it supplies excipients like poly vinyl pyrrolidone. These chemical products cater to a broad array of sectors, including pharmaceutical, agrochemical, paint and resin, animal feed, oil and gas, rubber cleaning, dye and textile, and water treatment industries. Beyond its chemical endeavors, the company also owns and manages Balaji Sarovar, a hotel property located in Solapur, Maharashtra, and is involved in the manufacturing and sale of CFL lamps. Balaji Amines maintains a significant international presence, exporting its goods to markets across the United States, Europe, China, Turkey, Korea, Malaysia, Kuwait, and other global regions. The company was founded in 1988 and is headquartered in Hyderabad, India.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Balaji Amines Limited (BALAMINES.NS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Balaji Amines Limited, an Indian company, specializes in the production and global distribution of methylamines, ethylamines, their associated derivatives, alongside a diverse portfolio of specialty chemicals and pharmaceutical excipients. The firm's business activities span three primary divisions: Amines & Speciality Chemicals, its Hotel operations, and CFL Lamp manufacturing. Within its chemical segment, Balaji Amines produces a wide range of amines, including monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, and dimethyl/diethyl amino ethanol. Its specialty chemicals encompass compounds like N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, and acetonitrile. Additionally, the company provides derivatives such as di-methyl acetamide, various amine hydrochlorides (di-methyl, tri-methyl, di-ethyl, tri-ethyl), di-methyl urea, and choline chloride. For the pharmaceutical industry, it supplies excipients like poly vinyl pyrrolidone. These chemical products cater to a broad array of sectors, including pharmaceutical, agrochemical, paint and resin, animal feed, oil and gas, rubber cleaning, dye and textile, and water treatment industries. Beyond its chemical endeavors, the company also owns and manages Balaji Sarovar, a hotel property located in Solapur, Maharashtra, and is involved in the manufacturing and sale of CFL lamps. Balaji Amines maintains a significant international presence, exporting its goods to markets across the United States, Europe, China, Turkey, Korea, Malaysia, Kuwait, and other global regions. The company was founded in 1988 and is headquartered in Hyderabad, India.
